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Abstract
Introduction: SARS-CoV-2 has been strongly associated with respiratory illnesses however 
the SARS-CoV-2 infection of the gastrointestinal tract is not fully clear. We examined the fre-
quency of positive stool SARS-CoV-2 RT-PCR in COVID-19 patients, duration of the stool viral 
shedding after the viral clearance of the respiratory samples and its association with gastroin-
testinal symptoms
Methods: We did a search in PubMed and Google Scholar of studies published in the English 
language before June 30th, 2020. Search queries included: “COVID-19”, “SARS-CoV-2”, and 
“stool SARS-CoV-2 RT-PCR”. We excluded studies with less than 8 patients from our review.
Results: Among the 707 patients who had respiratory samples positive for SARS-CoV-2, 361 
(51%) patients tested positive through stool SARS CoV-2 RT-PCR. From the 198 patients who 
tested positive for SARS-CoV-2 in stool, 101 (51%) patients continued testing positive after res-
piratory samples were negative through SARS-CoV-2 RT-PCR. The longest duration of positive 
SARS-CoV-2 in stool was 48 days and 33 days after the negative upper respiratory samples. 
Out of 200 patients who had positive fecal PCR for SARS-CoV-2, 95 patients (47.5%) had at 
least one gastrointestinal manifestation.
Conclusions: About a half of COVID-19 patients had positive stool SARS-CoV-2 RT-PCR and 
51% of patients had positive stool SARS CoV-2 RT-PCR after the respiratory samples became 
negative for SARS-CoV-2 RT-PCR. At least one GI symptom was reported in 47.5% of patients 
with a positive stool SARS-CoV-2 RT-PCR.
Introduction
The novel coronavirus (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS) and 
Middle East Respiratory Syndrome (MERS) were reported to have significant intestinal 
tropism and these three virus strains were detected in stool of patients. [1,2] Corman et 
al. examined adult patients infected with MERS-CoV and detected MERS-CoV RNA in 
14.6% of stool samples. [3] Furthermore, in-vitro studies using human primary intestinal 
epithelial cells of prior coronavirus outbreaks revealed sustained primary intestinal ep-
ithelial inflammation and massive viral replication with sequential development of lung 
infection via lymphatics and/or bloodstream. [4] As the emerging novel coronavirus has 
been identified, gastrointestinal symptoms became major findings. It has been reported 
that up to 79% of patients in Wuhan, China presented with gastrointestinal symptoms 
such as diarrhea, decreased appetite, nausea, vomiting, abdominal pain and gastrointes-
tinal bleeding. [5] This generated the hypothesis that the GI tract could be a major source 
of viral shedding and fecal-oral transmission. The first COVID-19 case reported in the 
WA, USA on January 20, 2020 experienced two loose bowel movements on day 6 of the 
illness. [6] Real-time reverse transcriptase PCR (rRT-PCR) for stool specimen came back 
positive for the SARS-CoV-2, before initiating any antiviral or antimicrobial therapy. In-
terestingly, higher loads of SARS-CoV-2 were detected in nasopharyngeal/ oropharyn-
geal swabs compared to the stool specimen. [6]
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It has been suggested that SARS-CoV-2 is at least as well adapted to the angiotensin converting enzyme 2 (ACE2) as 
the SARS-CoV, or even 10 to 20 fold higher binding affinity. [7-9] An immunofluorescent study by Xiao et al showed 
abundance of the ACE2 receptor and viral nucleocapsid proteins in the glandular cells of the stomach, duodenum and 
the rectum, however it is rarely expressed in the esophageal epithelium. [2] Detection of viral RNA in stool was con-
firmed in 39 out of 73 infected patients, which supports the release of infectious virions into the gastrointestinal tract. 
[2] Pathological changes were also another benchmark for gastrointestinal infiltration by the SARS-CoV-2. Segmental 
dilatation and stenosis of the small intestine to varying degrees of degeneration, necrosis and shedding of the gastroin-
testinal mucosa were identified. [10,11] In a GI endoscopy for an infected patient, retrieved tissues with H&E staining 
showed microscopically no significant damage of the mucous epithelium on numerous infiltrating plasma cells and 
lymphocytes with interstitial edema were detected. [2]
We reviewed the literature to determine the incidence of positive SARS-CoV-2 RT-PCR of COVID-19 patients, the du-
ration of fecal viral shedding even after the respiratory viral clearance and the frequency of gastrointestinal symptoms.
Materials and Methods
Study Design
This was a secondary analysis of studies published in English language peer-reviewed journals on COVID-19 that per-
formed stool SARS-CoV-2 RT-PCR tests.  
Database Search Strategies
We did a literature review for studies of patients with COVID-19 that reported positive stool SARS-CoV-2 in PubMed 
and Google Scholar published from April to June 30, 2020. Search queries included: “COVID-19”, “SARS-CoV-2”, and 
“stool SARS-CoV-2 RT-PCR”. 
Inclusion Criteria
Studies that examined patients with proven COVID-19 that reported stool SARS-CoV-2 RT-PCR test.
Exclusion Criteria
Studies with less than eight patients with positive stool SARS-CoV-2 RT-PCR. Institutional review board approval was 
not required given this study did not involve direct human participant research.
Results
COVID-19 patients tested for SARS-CoV-2 in stool samples.
Eighteen studies examined stool and respiratory samples for SARS-CoV-2 in patients with COVID-19 (Table 1). A to-
tal of 361 (51%) patients tested positive for SARS-CoV-2 in stool samples out of 707 patients positive for SARS-CoV-2 
in respiratory samples. Fourteen out of 18 studies were from China. The range of the number of study patients with 
COVID-19 was 8 – 93 and the range of the positive SARS-CoV-2 in stool was 15.3% to 100%. Six studies reported the 
gender of patients who had positive stool samples. Female patients with positive SARS-CoV-2 in stool were reported 
with a range of 35.9% to 62.5%. [2,12-16]
Duration of positive stool SARS-CoV-2 RT-PCR.
Chen et al. reported the median duration of 14 (9.5-18) days of SARS-CoV-2 detected in stool in severe cases, 8 (4.5-14) 
days in mild cases, and 9 days in patients with non-specific symptoms nor pneumonia. [12] Han et al. reported that 12 
patients with positive SARS-CoV-2 RT PCR in stool samples who had a longer duration of the COVID-19 symptoms 
compared with the ten patients with negative stool test (44.2 vs. 33.7 days, p=0.003). [13] Ling et al. identified 43 pa-
tients who had a median delay of 2 days for their positive stool samples to turn negative compared to the throat swabs. 
[17] The median duration of stool viral positivity was 11 (9-16) days. [17] Wu et al reported two patient continued to test 
positive in stool samples for 47 and 48 days after the onset of symptoms, with a total mean duration of 28.26±11.22. [14] 
Patients with positive stool SARS-CoV-2 RT-PCR after negative respiratory samples SARS-CoV-2 RT-PCR.
A total of six studies reported positive SARS-CoV-2 RT-PCR in stool after the respiratory SARS-CoV-2 RT-PCR became 
negative (Table 2). Out of 198 patients with positive stool RT-PCR, 101 patients (51%) had prolonged fecal viral shed-
ding after the respiratory samples RT-PCR. The mean and range of the positive stool SARS-CoV-2 RT-PCR were 51% 
and from 20.3% to 78% respectively. 
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Study Population Positive fecal RT-PCR*
Cheung et al. [19]
Gastroenterology,
Hong Kong, March 2020
59 9(15.3%)
Chen et al. [12]
Journal of Medical Virology,
China, March 2020
42 28(66.7%)
Ling et al. [17]
Chinese Medical Journal,
China, February 2020
66 54(81.8%)
Xiao et al. [2]
Gastroenterology,
China, February 2020
73 39(53.4%)
Zhang et al. [29]
Journal of Medical Virology,
China, March 2020
14 5(35.7%)
Han et al. [13]
American Journal of Gastroenterology,
China, March 2020
22 12(54.5%)
Wu et al. [14]
Lancet Gastroenterology and Hepatology,
China, March 2020
74 41(55.4%)
Wang et al. [27]
JAMA,
China, March 2020
13 5(38.5%)
Young et al. [30]
JAMA,
Singapore, March 2020
8 4(50%)
Xie et al. [15]
International Society for Infectious Diseases,
China, February 2020
9 8(88.9%)
Kim et al. [28]
Osong Public Health and Research 
Perspectives,
South Korea, April 2020
15 8(53.3%)
Long Lo et al. [31]
International Journal of Biological Sciences,
China, March 2020
10 10(100%)
Lin et al. [32]
Gut BMJ,
China, April 2020
65 10(100%)
Wei et al. [33]
Clinical Gastroenterology and Hepatology,
China, April 2020
84 28(33.3%)
Zheng et al. [20]
BMJ,
China, April 2020
93 55(59.14%)
Pan et al. [34]
Lancet Infectious Diseases,
China, April 2020
17 9(52.9%)
Kujawski et al. [35]
Nature Medicine,
USA, April 2020
10 7(70%)
Yin et al. [16]
Journal of clinical Virology,
China, April 2020
33 8(24.2%)
Total 707 361(51.0%)
Table 1. Total Number of COVID-19 Patients Who Tested Positive in Fecal RT-PCR for SARS-CoV-2.
*RT-PCR: Reverse Transcriptase Polymerase Chain Reaction
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Gastrointestinal Symptoms and positive stool SARS-CoV-2 RT-PCR.
Nine studies reported the presence of gastrointestinal symptoms in COVID-19 patients, either as sole presentation or 
in combination with respiratory symptoms, see table 3. Among a total of 200 patients who tested positive for SARS-
CoV-2 through stool samples, 95 (47.5%) patients had at least one gastrointestinal symptom. The GI symptoms were di-
arrhea, anorexia, abdominal pain, nausea, vomiting or GI bleeding. Anorexia and diarrhea were the most prevalent GI 
symptoms. [11,18] Patients with positive SARS-CoV-2 in stool had no higher occurrence of GI symptoms compared to 
those tested negative as per Chen et al. [12] Meanwhile, patients presenting with gastrointestinal symptoms were more 
likely to test positive for fecal virus (73.3% vs. 14.3%, p=0.033) where 11 out of 12 patients with positive fecal samples 
had digestive symptoms. [13] The proportion of patients with detectable stool viral RNA was higher among those with 
diarrhea than those without diarrhea, and 38% of patients experiencing  diarrhea tested positive for fecal RT-PCR. [19] 
Among 39 patients tested positive for SARS-CoV-2 in stool samples by Xiao et al, 21 patients had GI symptoms (54%), 
of which 17 had diarrhea and 4 manifested with GI bleeding. [2] Controversially, in a pool of 74 COVID-19 positive pa-
tients the presence of gastrointestinal symptoms was not associated with fecal sample viral RNA positivity (p=0·45). 
[14] Larger scale studies are required to come to a more reasonable answer addressing the relation of gastrointestinal 
symptoms to the possibility of positive fecal testing.
Discussion
Our review included a total of 18 studies of patients with COVID-19 and positive SARS-CoV-2 RT-PCR in stool. These 
studies were predominantly from China and included a relatively small number of patients. Our study revealed that 
about 50% of patients with COVID-19 have positive stool SARS-CoV-2 RT-PCR. Factors affecting fecal viral shedding is 
a topic still under research, but may be affected by antiviral regimens, gastrointestinal genetic susceptibility, microbiota 
or corticosteroid management. Ling et al have tested five patients who received corticosteroids during hospitalization. 
The duration of viral RNA detection for throat swabs and feces in the corticosteroid treatment group was longer than 
that in the non-corticosteroid treatment group, which were 15 days compared to 8.0 days (P =0.013) and 20 days com-
Study Positive fecal RT-PCR* (%)
Patients with fecal viral shedding after 
Negative Respiratory Sample (%)
Chen et al. [12] 28 (66.7%) 18 (64.3%)
Ling et al. [17] 54 (81.8%) 11 (20.3%)
Xiao et al. [2] 39 (53.4%) 17 (43.6%)
Wu et al. [14] 41 (55.4%) 32 (78%)
Kim et al. [28] 8 (53.3%) 3 (37.5%)
Wei et al. [33] 28 (33.3%) 20 (71.4%)
Total 198 101 (51%)
Table 2. Number of Patients with Positive Fecal RT-PCR and Continuous Viral Shedding After Negative 
Respiratory Samples.
Table 3. Number of Patients with Positive Fecal RT-PCR and Concurrent GI Symptoms
Study Positive fecal RT-PCR* (%)
Patients with at least one concurrent GI 
symptom and positive fecal RT-PCR (%)
Chen et al. [12] 28 (66.7%) 6 (21.4%)
Xiao et al. [2] 39 (53.4%) 21 (53.8%)
Zhang et al. [29] 5 (35.7%) 0 (0%)
Han et al. [13] 12 (54.5%) 11 (91.7%)
Wu et al. [14] 41 (55.4%) 11 (26.8%)
Xie et al. [15] 8 (88.9%) 1 (12.5%)
Lin et al. [32] 31 (47.7%) 22 (71%)
Wei et al. [33] 28 (33.3%) 18 (64.3%)
Yin et al. [16] 8 (24.2%) 5 (62.5%)
Total 200 95 (47.5%)
*RT-PCR: Reverse Transcriptase Polymerase Chain Reaction
*RT-PCR: Reverse Transcriptase Polymerase Chain Reaction
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pared to 11 days (P <0.001), respectively. [17]
The duration of viral shedding was significantly higher in patients treated with glucocorticoids for more than 10 days 
compared to those received treatment for less than 10 days. [20] This could be a recommendation against steroid man-
agement if no other comorbid conditions require such treatment.
Our study revealed the range duration of 4.5 to 48 days of positive stool SARS-CoV-2 RT-PCR in patients with COVID-19 
and 51% of the cases had positive tests after the respiratory tests turned negative. Chen et al identified that patients who 
tested positive in stool samples can continue fecal viral shedding after negative conversion in respiratory samples for 6 
to 10 days. [12] Wu et al. reported that the stool of 4 out of 41 patients turned negative for SARS CoV-2 before the respi-
ratory samples. [14] In the same series, 32 patients continued with fecal shedding of the virus after the respiratory sam-
ples tested negative, while the respiratory and stool samples of 5 patients turned negative on the same day. In addition, 
one patient continued testing positive in stool for 33 days after negative respiratory samples. Xiao et al reported that 17 
out of 39 patients (44%) who tested positive for SARS-CoV-2 by RT-PCR continued testing positive for SARS-CoV-2 af-
ter their respiratory samples turned negative. [2] It has been evident that viral detection in stool usually extends beyond 
that of the respiratory samples, however an exact pathophysiology is not yet clear. The longest duration of SARS CoV-2 
RT-PCR positive in stool was 48 days and the longest viral positive stool after clearance of the upper respiratory sam-
ples was 33 days. [14] This adds more concern about when to announce to a patient that is free of the COVID-19 disease. 
Our study revealed that a mean of 47.5% of patients with positive stool SARS-CoV-2 RT-PCR had at least one GI symp-
tom either as a sole presentation or in combination with the respiratory symptoms. Interestingly, only 47% of patients 
with positive fecal RT-PCR for SARS-CoV-2 had gastrointestinal symptoms. Current protocols encourage discharging 
infected patients after relief of symptoms and double negative RT-PCR testing of nasopharyngeal swabs. However, 
this can be not a favorably safe outcome in controlling further viral transmission, especially after proving positive anal 
swabs in the setting of negative oral test. 
It is still debatable whether the virus is viable in stool specimen of infected patients, and if could remain viable in the 
environment or become a direct threat for fecal-oral transmission. Detection of viral RNA in specimens cannot always 
correlate with possible viral transmissibility. Given the current pandemic situation, viral cultures for the novel corona-
virus are too difficult and hazardous, which is critical to differentiate between infective and non-infective viruses. [21] 
Studies on MERS-CoV and SARS CoV have shown capability of detecting viral nucleic acid from sewage, low tempera-
ture and low humidity surfaces that may favor fecal-oral transmission. [22,23] A recently published viability study in a 
Biosafety level 3 lab in China was able to isolate a live virus from a stool specimen of a laboratory-confirmed COVID-19 
severe pneumonia case. [24] Another two independent laboratories in China declared that they have successfully iso-
lated live SARS-CoV-2 from the stool of patients. [25] Molecular and serological investigation on both oral and anal 
swabs were able to detect the viral nucleotide in anal swabs. Zhang et al tested 15 patients who had positive oral swabs 
upon admission, 4 out of those 15 patients (26.7%) had positive anal swab testing, with two of them tested negative 
in oral swab on the same day of testing. [26] Wang et al reported cultures from four SARS-CoV-2 stool samples and 
observed live virus in two of them by electron microscopy. [27] However Kim et al was not able to isolate stool SARS-
CoV-2 cultured in CaCo-2 cells for 5 days. [28] More research is needed to identify the presence of live virus in the stool 
of COVID-19 patients and potential fecal-oral route of transmission.
The issue of viral viability is still under further biological and molecular investigation although it was proven in bio-
safety laboratories in China. Understanding the favorable environmental conditions in terms of temperature, humid-
ity or other factors that may contribute to the viability of SARS-CoV-2 would be of definite interest to control viral 
transmission. In the meantime, patients should be educated about the possibility of fecal-oral transmission and hand 
washing often. Asymptomatic patients or those presenting only with digestive symptoms may represent a higher viral 
load in the GI tract and measurably higher probability of fecal-oral transmission. This should be taken into consider-
ation in the outpatient setting and digestive diseases health facilities. We should not underestimate patients living in 
wide-spread communities presenting solely with digestive complaints or in addition to the common upper respiratory 
symptoms. Those patients could benefit of fecal testing to determine if they are shedding the virus. This can add to 
strict infection control measures to minimize spread. Initial RT-PCR fecal testing could be implemented as a screening 
tool especially for patients showing suspicious digestive symptoms and a negative nasopharyngeal swab. Follow-up fe-
cal testing as well could also be a valuable tool to decide upon termination of isolation restrictions. Proper sterilization 
techniques and open ventilation systems should be always recommended in public restrooms, hospital sewage systems 
and senior or students housing.
Our study has some strengths and limitations. One of the strengths of our study is that to our knowledge this is the 
most updated review of GI COVID-19 and positive stool SARS-CoV-2 RT-PCR that included studies published until 
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/61 6
ULJRI Positive SARS-CoV-2 in Stool Samples
June 30, 2020. Also, in our review we reported the largest pool of 707 COVID-19 patients tested in stool samples for 
SARS-CoV-2, among other published reviews. Some of the weaknesses are the fact that most of the studies are from 
China and only one study from the US therefore this is a limitation for the data generalizability. Secondly, all the studies 
were observational with a small sample size. Regardless of these limitations, our study is very timely for enhancing the 
knowledge of GI COVID-19 in relation to the presence of positive stool SARS-CoV-2 RT-PCR. 
In conclusion, our study suggests that about a half of COVID-19 patients have positive stool SARS-CoV-2 RT-PCR 
and 51% of patients have positive stool SARS-CoV-2 RT-PCR after the respiratory samples became negative for SARS-
CoV-2 RT-PCR. In addition, at least one GI symptom was reported in 47.5% of patients with positive stool SARS-CoV-2 
RT-PCR.
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